BioRestorative Therapies, Inc. (BRTX)

Over the past six months, BRTX stock has trended down. In Q3 2025, the company reported decreased revenues but exceeded EPS expectations. A registered direct offering in October 2025 strengthened the financial position but triggered dilution fears. In Q2 2025, the company reported increased revenues due to BioCosmeceutical sales. A $2 million stock repurchase program was announced in August 2025. In Q1 2025, the company reported a 100% beat on EPS estimates.

There is no explicit information indicating significant demand seasonality for BioRestorative Therapies, Inc.'s primary product candidates. Variability in BioCosmeceutical sales is related to the timing of orders. Demand is typically driven by clinical trial progress, regulatory approvals, and medical need rather than seasonal consumer trends.

BioRestorative Therapies, Inc. (BRTX) is a biotechnology company focused on developing regenerative medicine products and therapies primarily utilizing adult stem cells, operating within the Healthcare sector, specifically the Biotechnology industry, with core development programs including the Disc/Spine Program and the Metabolic Program. Its lead cell therapy candidate, BRTX-100, is in Phase 2 clinical trial for chronic lumbar disc disease and has received FDA Fast Track designation. ThermoStem is a cell-based therapy candidate designed to target obesity and metabolic disorders. The company also operates a commercial biocosmeceutical platform and has licensed an investigational curved needle device.

BioRestorative Therapies, Inc. is headquartered in Melville, New York, United States, and its Phase 2 clinical trial for BRTX-100 is being conducted at up to 16 clinical sites across the United States. The company's intellectual property extends internationally, as evidenced by the Japanese Patent Office issuing a Notice of Allowance for its ThermoStem® platform.

BioRestorative Therapies has experienced events that could positively impact its brand reputation. The FDA Fast Track Designation for BRTX-100 is a significant positive. The Japanese Patent for ThermoStem expands intellectual property protection. Leadership appointments and industry participation aim to accelerate growth and raise the company's profile. Preliminary clinical data showed positive trends in pain and disability metrics.

BioRestorative Therapies, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold approximately 4.28% to 69.38% of the stock. Insiders hold a significant portion of the company's stock. Westbury Bermuda Ltd is the largest individual shareholder.